Skip to main content
OpenTrials

Clinical trial condition

Hypertension

Explore clinical trials studying Hypertension. Study availability and eligibility vary by location and protocol.

4,647 public trials 456 recruiting studies
Refine in advanced search Browse all conditions

Hypertension trial results

Completed

An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

NCT01103960

Conditions
Cardiovascular Diseases, Hypertension, Vascular Diseases
Locations
  • 1235.29.86001 Boehringer Ingelheim Investigational Site Beijing, China
  • 1235.29.86004 Boehringer Ingelheim Investigational Site Beijing, China
  • 1235.29.86006 Boehringer Ingelheim Investigational Site Changchun, China
  • 1235.29.86013 Boehringer Ingelheim Investigational Site Changsha, China
View all 16 locations
View Trial Details
Completed

Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

NCT01286558

Conditions
Cardiovascular Diseases, Hypertension, Vascular Diseases
Locations
  • 1235.37.01 Boehringer Ingelheim Investigational Site Chuo-ku,Tokyo, Japan
  • 1235.37.07 Boehringer Ingelheim Investigational Site Hiroshima, Hiroshima, Japan
  • 1235.37.08 Boehringer Ingelheim Investigational Site Itoshima, Fukuoka, Japan
  • 1235.37.02 Boehringer Ingelheim Investigational Site Katsushika-ku, Tokyo, Japan
View Trial Details
Completed

Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

NCT00558428

Conditions
Cardiovascular Diseases, Hypertension, Vascular Diseases
Locations
  • 1235.5.32004 Boehringer Ingelheim Investigational Site Aywaille, Belgium
  • 1235.5.32001 Boehringer Ingelheim Investigational Site Brussels, Belgium
  • 1235.5.32010 Boehringer Ingelheim Investigational Site Gozée, Belgium
  • 1235.5.32008 Boehringer Ingelheim Investigational Site Linkebeek, Belgium
View all 129 locations
View Trial Details
Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

NCT00618774

Conditions
Cardiovascular Diseases, Hypertension, Vascular Diseases
Locations
  • 1235.16.004 Boehringer Ingelheim Investigational Site Chofu, Tokyo, Japan
  • 1235.16.006 Boehringer Ingelheim Investigational Site Nishi-ku, Hiroshima, Hiroshima, Japan
  • 1235.16.005 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan
  • 1235.16.007 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan
View Trial Details
Completed

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289

Conditions
Cardiovascular Diseases, Hypertension, Vascular Diseases
Locations
  • 502.550.01008 Boehringer Ingelheim Investigational Site Athens, Alabama, United States
  • 502.550.01019 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 502.550.01015 Boehringer Ingelheim Investigational Site Lomita, California, United States
  • 502.550.01003 Boehringer Ingelheim Investigational Site Colorado Springs, Colorado, United States
View all 106 locations
View Trial Details
Completed

Telmisartan 80mg Non-responder Trial

NCT01222520

Conditions
Cardiovascular Diseases, Hypertension, Vascular Diseases
Locations
  • 1235.36.01 Boehringer Ingelheim Investigational Site Chuo-ku,Tokyo, Japan
  • 1235.36.04 Boehringer Ingelheim Investigational Site Hiroshima, Hiroshima, Japan
  • 1235.36.02 Boehringer Ingelheim Investigational Site Shinjuku-ku, Tokyo, Japan
  • 1235.36.03 Boehringer Ingelheim Investigational Site Suita, Osaka, Japan
View Trial Details

Related conditions